- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01328990
Pharmacokinetics of Sulfadoxine-pyrimethamine Plus Amodiaquine for Intermittent Preventive Treatment in Children (IPTc)
September 16, 2011 updated by: London School of Hygiene and Tropical Medicine
Pharmacokinetics of Sulfadoxine-pyrimethamine Plus Amodiaquine When Used for Malaria Intermittent Preventive Treatment in Children
The aim of the study is to determine the pharmacokinetic profile of sulfadoxine-pyrimethamine plus amodiaquine (SP+AQ) when used for seasonal Intermittent Preventive Treatment (IPT) to prevent malaria in children aged 3 to 59 months in Lamarame, NDoffane District, Senegal.
Several studies have shown that seasonal IPT in children can provide a high degree of protection against clinical malaria.
SP+AQ is the most effective regimen.
However little is known about the pharmacokinetics of amodiaquine and sulfadoxine-pyrimethamine in children.
The purpose of this study is to determine the pharmacokinetics profile of SP+AQ when used for IPT in Senegalese children.
150 children aged 3 to 59 months will be enrolled in November.
They will receive a therapeutic dose of sulfadoxine-pyrimethamine and amodiaquine, and will be followed up for 30 days.
Four finger prick blood samples will be taken from each child for PK analysis.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
SP+AQ is the most effective regimen for IPT in children, but there is little information about the pharmacokinetics of these drugs in children.
Although this combination has been used for many years for treatment of clinical malaria there have been no studies of the pharmacokinetics of this combination.
A recent study described the pharmacokinetics of amodiaquine when used in combination with artesunate to treat children with clinical malaria (Stepniewska et al, 2009), and another recent study described the pharmacokinetics of SP in children with malaria (Barnes et al, 2006), and a further study of SP in children with uncomplicated malaria demonstrated a low plasma level of the drug in children who failed the treatment (Obua et al. 2008), but there are no studies of these drugs given together or in healthy children.
This information is important in order to check the bioavailability of the two drugs when used for IPT and to check the adequacy of the currently recommended dosage.
The study will be conducted in a rural district of Senegal, after holding community meetings to explain the study.
150 children aged 1-5 years, boys and girls who do not have history of allergy to study drugs and whose parents agreed for them to participate will be enrolled at the study clinic.
The sample size determination is based on experience from other PK studies.
During the study organization phase, meetings will be held at the health facilities, members of the community, community leaders, and health staff will be invited to attend, the investigators will explain, in local language, the aims of the study, the recruitment and follow up procedures, the total sample size needed, and the duration of follow up.
The detailed schedule for blood sampling will be explained.
Subsequently the investigators will visit families at home to explain the study and invite people to attend at the clinic.
Mothers or carers will be asked to bring the child to the clinic where, after signing to indicate consent, the child will be weighed and have a clinical examination, a finger prick blood sample will be taken by drawing blood into a vacutainer, from which 70µL of blood will be pipetted onto filter paper.
SP and the first dose of AQ will be administered according to the child's weight, the child will be kept under observation for 30 minutes before being allowed to return home.
The remaining doses of amodiaquine (days 1 and 2) will be given to a field worker who will visit the child at home to supervise drug administration.
The exact time of the administration will be recorded.
Any child who vomits a dose will be given a repeat dose.
The child will be asked to provide a finger prick blood sample on three further occasions between day 1 and day 28, determined according to a schedule chosen to allow good estimation of PK parameters.
Trained field staff will visit each child on day 4, to ask about any adverse reactions to the drugs, and on day 14 and 28 to check the child is well.
Children with signs of severe malaria, or any other severe illness, will be referred immediately to the health post.
For other children, if the child has axillary temp >=37.5oC or a history of fever in the last 48 hours a finger prick blood sample will be taken for malaria diagnosis by rapid test and blood film to be read later.
Children with a positive test will be treated with Coartem.
Study Type
Interventional
Enrollment (Actual)
150
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Dakar, Senegal
- Universite Chiekh Anta Diop
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
1 year to 3 years (Child)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- age 3 months to 5 years
- no allergy to study drugs
- consent from parent or guardian
Exclusion Criteria:
- chronic illness
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Concentration of sulfadoxine, pyrimethamine, and desethylamodiaquine
Time Frame: 28 days
|
Concentration of the drugs will be measured at four time points.
|
28 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Tolerability
Time Frame: 28 days
|
Adverse events will be recorded during home visits
|
28 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Study Chair: Badara Cisse, PhD, Universite Chiekh Anta Diop
- Study Director: Paul Milligan, PhD, London School of Hygiene and Tropical Medicine
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2011
Primary Completion (Actual)
July 1, 2011
Study Completion (Actual)
July 1, 2011
Study Registration Dates
First Submitted
April 4, 2011
First Submitted That Met QC Criteria
April 4, 2011
First Posted (Estimate)
April 5, 2011
Study Record Updates
Last Update Posted (Estimate)
September 19, 2011
Last Update Submitted That Met QC Criteria
September 16, 2011
Last Verified
September 1, 2011
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Infections
- Vector Borne Diseases
- Parasitic Diseases
- Protozoan Infections
- Malaria
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Antiprotozoal Agents
- Antiparasitic Agents
- Antimalarials
- Folic Acid Antagonists
- Anti-Infective Agents, Urinary
- Renal Agents
- Pyrimethamine
- Sulfadoxine
- Fanasil, pyrimethamine drug combination
- Amodiaquine
Other Study ID Numbers
- IZ5856
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Malaria
-
University of California, San FranciscoCenters for Disease Control and Prevention; University of Massachusetts, Amherst and other collaboratorsRecruitingPlasmodium Falciparum Malaria | Plasmodium Vivax MalariaLao People's Democratic Republic
-
Medicines for Malaria VentureAsociacion Civil Selva AmazonicaCompletedPlasmodium Falciparum Malaria | Plasmodium Vivax MalariaPeru
-
Menzies School of Health ResearchInternational Centre for Diarrhoeal Disease Research, Bangladesh; Addis Ababa... and other collaboratorsCompletedMalaria | Vivax Malaria | Falciparum MalariaEthiopia, Bangladesh, Indonesia
-
University of OxfordWellcome Trust; Ministry of public Health AfghanistanCompletedVivax Malaria | Uncomplicated Falciparum MalariaAfghanistan
-
Gadjah Mada UniversityMenzies School of Health Research; Eijkman Institute for Molecular Biology; Timika...Completed
-
Menzies School of Health ResearchNational Health and Medical Research Council, Australia; Wellcome Trust; National...CompletedVivax Malaria | Falciparum MalariaIndonesia
-
London School of Hygiene and Tropical MedicineWorld Health Organization; United Nations High Commissioner for Refugees; HealthNet... and other collaboratorsCompletedMalaria | Vivax Malaria | Falciparum MalariaPakistan
-
Menzies School of Health ResearchNational Health and Medical Research Council, Australia; Wellcome Trust; National...CompletedVivax Malaria | Falciparum MalariaIndonesia
-
University of IbadanShin Poong Pharm Co Ltd 161 yoksam-ro, Gangnam-Gu Seoul 135-925, Korea; Institute...CompletedPlasmodium Falciparum Malaria | Uncomplicated Malaria | Malaria FeverNigeria
-
Research Institute for Tropical Medicine, PhilippinesWorld Health OrganizationCompletedTES of Artemether-lumefantrine for Pf and Chloroquine for Pv in the Philippines From 2013-2014 (TES)Malaria | Vivax Malaria | Falciparum Malaria | Malaria Recrudescence
Clinical Trials on sulfadoxine-pyrimethamine plus amodiaquine
-
London School of Hygiene and Tropical MedicineCheikh Anta Diop University, SenegalCompleted
-
Malaria ConsortiumNot yet recruitingMalaria,Falciparum | Chemoprevention
-
London School of Hygiene and Tropical MedicineMedical Research Council; National Malaria Control Programme, The GambiaCompleted
-
London School of Hygiene and Tropical MedicineCheikh Anta Diop University, Senegal; Institut de Recherche pour le Developpement and other collaboratorsUnknown
-
London School of Hygiene and Tropical MedicineMedical Research CouncilCompleted
-
Centers for Disease Control and PreventionMinistry of Health and Population, MalawiCompleted
-
Centers for Disease Control and PreventionMalaria Research and Training Center, Bamako, MaliCompleted
-
London School of Hygiene and Tropical MedicineWellcome Trust; Medical Research Council Unit, The Gambia; University of Ilorin...CompletedMalaria | Sickle Cell CrisisNigeria
-
Alliance for International Medical ActionInstitut National de la Santé Et de la Recherche Médicale, France; United States... and other collaboratorsCompleted
-
London School of Hygiene and Tropical MedicineUganda Malaria Surveillance Project; Ministry of Health, UgandaCompletedMalaria | Intermittent Preventive Treatment